A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Gold MA, Brady WE, Lankes HA, Rose PG, Kelley JL, De Geest K, Crispens MA, Resnick KE, Howell SB
Gynecol Oncol. 2012 125 (3): 635-9

PMID: 22446624 · PMCID: PMC4370623 · DOI:10.1016/j.ygyno.2012.03.023

MeSH Terms (15)

Adult Aged Carcinoma, Ovarian Epithelial Disease-Free Survival Fallopian Tube Neoplasms Female Humans Hyaluronan Receptors Middle Aged Neoplasm Recurrence, Local Neoplasms, Glandular and Epithelial Ovarian Neoplasms Peptide Fragments Peritoneal Neoplasms Urokinase-Type Plasminogen Activator

Connections (1)

This publication is referenced by other Labnodes entities: